Nordion, Inc. has signed a three-year contract with Navidea Biopharmaceuticals to manufacture NAV5001, a diagnostic imaging agent used to detect Parkinsonian Syndromes and Dementia with Lewy Bodies. The agreement includes a facility preparation and readiness phase and a clinical trial supply phase. The manufacture of NAV5001 is expected to support Navidea’s Phase IIb and Phase III trials scheduled to begin in 2013. Nordion is also responsible for managing the logistics of NAV5001 to third-party ...